Hims & Hers Health/$HIMS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Hims & Hers Health

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.

Ticker

$HIMS
Sector

Primary listing

NYSE

Employees

1,637

HIMS Metrics

BasicAdvanced
$13B
70.36
$0.79
2.09
-

What the Analysts think about HIMS

Analyst ratings (Buy, Hold, Sell) for Hims & Hers Health stock.

Bulls say / Bears say

Diversification into new specialties and diagnostics: CEO Andrew Dudum is targeting under-insured consumers by launching a diagnostics lab and expanding into low testosterone and menopause treatments, reducing reliance on GLP-1 compounding and broadening the platform’s addressable market. (Reuters)
Ambitious long-term growth target: Hims & Hers projects revenue of $6.5 billion by 2030, underscoring confidence in its scalable telehealth platform and the ability to expand beyond core weight-loss offerings. (Reuters)
Resilience amid regulatory headwinds: Following the FDA ban on compounded Wegovy, Hims & Hers achieved a 111% increase in Q1 2025 revenue and is exploring partnerships with Novo Nordisk while entering high-growth markets such as sleep, longevity, and hormone health to sustain momentum. (Reuters)
Execution risk highlighted by Q2 revenue miss: Second-quarter revenue of $544.8 million fell short of the $552 million consensus, triggering a 12% stock decline and signaling potential difficulty in meeting analyst expectations. (WSJ)
Regulatory threat to core product: The FDA’s resolution of the semaglutide shortage and ban on compounded versions effective May 22, 2025 undermines a key GLP-1 weight-loss revenue stream, creating significant uncertainty for future sales. (Reuters)
Legal and competitive risks: Analysts question the legitimacy of Hims & Hers’ personalized compounding dosages and warn of potential legal challenges from Novo Nordisk, which could lead to further partnership terminations and hinder the GLP-1 business model. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.

HIMS Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

HIMS Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HIMS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs